[go: up one dir, main page]

WO2018174125A1 - Composition pour améliorer le métabolisme des lipides - Google Patents

Composition pour améliorer le métabolisme des lipides Download PDF

Info

Publication number
WO2018174125A1
WO2018174125A1 PCT/JP2018/011280 JP2018011280W WO2018174125A1 WO 2018174125 A1 WO2018174125 A1 WO 2018174125A1 JP 2018011280 W JP2018011280 W JP 2018011280W WO 2018174125 A1 WO2018174125 A1 WO 2018174125A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
streptococcus thermophilus
improving
lipid metabolism
lactic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2018/011280
Other languages
English (en)
Japanese (ja)
Inventor
直也 高梨
弘樹 村上
曉▲イン▼ 雷
貴幸 奈良
瀬戸　泰幸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Megmilk Snow Brand Co Ltd
Original Assignee
Megmilk Snow Brand Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Megmilk Snow Brand Co Ltd filed Critical Megmilk Snow Brand Co Ltd
Priority to JP2019506952A priority Critical patent/JP7606276B2/ja
Publication of WO2018174125A1 publication Critical patent/WO2018174125A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Definitions

  • the present invention relates to a lipid metabolism improving composition containing lactic acid bacteria belonging to Streptococcus thermophilus and foods, pharmaceuticals and feeds containing such a composition. Moreover, it is related with the composition which improves the metabolic syndrome containing the lactic acid bacteria which belong to Streptococcus thermophilus.
  • Fatty liver is a general term for diseases in which neutral fat is excessively deposited in the liver and causes liver damage, and is known to develop due to various factors such as excessive intake of alcohol, obesity, diabetes, and drugs.
  • NAFLD non-alcoholic fatty liver disease
  • the cause of fat accumulation in the liver is mainly due to the inflow of fat accumulated in adipose tissue into the liver.
  • increased fat synthesis in the liver is also a major cause, reaching 25% of the fat accumulated in the liver.
  • This enhancement of fat synthesis controls the expression of fatty acid synthesis-related genes such as acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), stearyl-CoA desaturase 1 (SCD1) and the expression of these fatty acid synthesis-related genes.
  • SREBP-1c which is a transcription factor is involved. When insulin resistance is induced by obesity or metabolic syndrome, SREBP-1c is induced and the expression of fatty acid synthesis-related genes is increased, resulting in fat accumulation in the liver.
  • Patent Document 1 discloses a culture (a) obtained by culturing a culture medium containing at least whey protein and skim milk with Lactobacillus rhamnosus GG strain (ATCC 53103), and Lactobacillus casei TMC0409 strain (FERM P-17047).
  • B a culture comprising the culture medium (c) cultured with Streptococcus thermophilus TMC1543 strain (FERM P-17046) and a calcium preparation, and containing calcium in milk solids.
  • the functional food / beverage products which have the body fat accumulation suppression and the anti-obesity effect characterized by the said ratio being 1.5 weight% or more are disclosed.
  • lactic acid bacteria are used as a prophylactic / therapeutic agent for Nonalcoholic steatohepatitis (NASH), which is a case in which hepatic tissue is accompanied by steatohepatitis associated with balloon-like swelling of hepatocytes and is at high risk of becoming cirrhosis or liver cancer.
  • NASH Nonalcoholic steatohepatitis
  • mice were ingested with a high fat diet containing ⁇ 10 10 / g for 12 weeks so that the daily intake was 3 g, and from the 9th week to the 12th week from the start of administration of the lactic acid bacteria-containing high fat diet
  • a high fat diet containing ⁇ 10 10 / g for 12 weeks so that the daily intake was 3 g, and from the 9th week to the 12th week from the start of administration of the lactic acid bacteria-containing high fat diet
  • first time 0.05 ml / kg BW (body weight)
  • second and subsequent times 0.1 ml / kg BW
  • a NASH prophylactic / therapeutic agent comprising a lactic acid bacterium whose serum ALT value is reduced by 65% or more as compared with a mouse is disclosed.
  • Patent Document 3 aims to provide an agent for promoting differentiation from stem cells to brown adipocytes, which can improve and prevent obesity and metabolic syndrome, from stem cells containing catechins as active ingredients to brown adipocytes.
  • Differentiation promoters, pharmaceuticals containing the differentiation promoters, quasi drugs, cosmetics and foods and drinks are disclosed as solution means.
  • Patent document 4 aims to provide a composition for enhancing or increasing muscles or improving metabolic syndrome and improving QOL, and a composition comprising triterpenes and polyphenols, preferably oleanolic acid and oleuropein
  • pharmaceutical compositions and foods containing the composition are disclosed as solving means.
  • Patent Document 1 the lactic acid bacteria culture of Patent Document 1 is a mixture of the above three types of lactic acid bacteria cultures (a) to (c), and it is unclear which lactic acid bacteria have body fat accumulation suppression and anti-obesity effects. there were.
  • Patent Document 2 mentions Streptococcus thermophilus as the lactic acid bacterium to be tested, but has verified the effect on liver damage induced by carbon tetrachloride, and does not describe any effect of improving lipid metabolism. It was. That is, no means for improving lipid metabolism using lactic acid bacteria has been reported in Patent Document 1 or Patent Document 2. Therefore, there has been a demand for means for improving lipid metabolism using lactic acid bacteria.
  • the first problem of the present invention is as a new solution for improving lipid metabolism, a composition for improving lipid metabolism, comprising a lactic acid bacterium belonging to Streptococcus thermophilus as an active ingredient, and a food for improving lipid metabolism comprising the composition Providing pharmaceuticals and feed.
  • Non-Patent Document 2 discloses white adipocytes and brown adipocytes, but no method for improving adipocyte metabolism using lactic acid bacteria has been reported.
  • Patent Documents 3 and 4 disclose methods for improving and preventing metabolic syndrome, but no method using lactic acid bacteria has been reported. For this reason, there has been a demand for improvement and prevention of a method for improving metabolism of adipocytes and metabolic syndrome using lactic acid bacteria.
  • the second object of the present invention is to provide a composition for improving the metabolism of a new adipocyte and a food, a pharmaceutical and a feed for improving the metabolism of an adipocyte comprising such a composition.
  • a second object of the present invention is to provide a composition for improving a new metabolic syndrome, and a food, a medicine and a feed for improving the metabolic syndrome including the composition.
  • a composition for improving lipid metabolism comprising, as an active ingredient, a culture of lactic acid bacteria and / or bacterial cells belonging to Streptococcus thermophilus (Streptococcus thermophilus).
  • the lactic acid bacterium belonging to Streptococcus thermophilus is Streptococcus thermophilus SBT1
  • the composition for improving lipid metabolism according to (A1) which is any one of 277 (FERM BP-03234) and SBT1063 (NITE P-02398).
  • (A3) The composition for improving lipid metabolism according to (A1) or (A2), wherein the lipid metabolism is lipid metabolism in the liver.
  • a food for improving lipid metabolism comprising the composition for improving lipid metabolism according to any one of (A1) to (A3).
  • a drug for improving lipid metabolism comprising the composition for improving lipid metabolism according to any one of (A1) to (A3).
  • a lipid metabolism improving feed comprising the lipid metabolism improving composition according to any one of (A1) to (A3).
  • the present inventors have conducted extensive studies on a composition that suppresses accumulation of excess fat and obesity in a living body and a composition that improves metabolic syndrome, and as a result, Streptococcus thermophilus The present invention was completed by finding that these have an improving action. That is, the second invention relates to the following contents.
  • (B1) A composition for promoting differentiation from white adipose precursor cells to brown adipocytes, comprising a lactic acid bacteria culture and / or cells belonging to Streptococcus thermophilus as an active ingredient.
  • (B2) The composition according to (B1), wherein the lactic acid bacterium belonging to Streptococcus thermophilus is Streptococcus thermophilus SBT1277 (FERM BP-03234).
  • (B3) A composition for activating brown adipocytes comprising a culture of lactic acid bacteria belonging to Streptococcus thermophilus and / or bacterial cells as an active ingredient.
  • (B4) The composition according to (B3), wherein the lactic acid bacterium belonging to Streptococcus thermophilus is Streptococcus thermophilus SBT1277 (FERM BP-03234).
  • (B5) A composition for improving metabolic syndrome, comprising a culture of lactic acid bacteria and / or cells belonging to Streptococcus thermophilus as an active ingredient.
  • the lactic acid bacterium belonging to Streptococcus thermophilus is Streptococcus thermophilus SBT1277 (FERM BP-03234).
  • (B7) A food for promoting differentiation from white adipose precursor cells to brown adipocytes, comprising the composition according to (B1) or (B2).
  • (B8) A pharmaceutical product for promoting differentiation from white adipose precursor cells to brown adipocytes, comprising the composition according to (B1) or (B2).
  • a feed for promoting differentiation from white adipose precursor cells to brown adipocytes comprising the composition according to (B1) or (B2).
  • B10 A food product for activating brown adipocytes, comprising the composition according to (B3) or (B4).
  • B11) A pharmaceutical product for activating brown adipocytes, comprising the composition according to (B3) or (B4).
  • B12 A feed for activating brown adipocytes, comprising the composition according to (B3) or (B4).
  • B13) A food for improving metabolic syndrome comprising the composition according to (B5) or (B6).
  • B14 A drug for improving metabolic syndrome, comprising the composition according to (B5) or (B6).
  • a feed for improving metabolic syndrome comprising the composition according to (B5) or (B6).
  • the second problem includes the configuration of a fatty acid synthesis inhibitor, a cholesterol synthesis inhibitor, a gluconeogenesis inhibitor, or an adipose tissue inflammation inhibitor containing lactic acid bacteria belonging to Streptococcus thermophilus as an active ingredient. .
  • the first invention provides a lipid metabolism improving composition containing lactic acid bacteria belonging to Streptococcus thermophilus and a lipid metabolism improving food, pharmaceutical and feed containing the composition as a new solution for improving lipid metabolism To do. Therefore, improvement of lipid metabolism can be expected in a simple and safe manner by ingesting the above composition, food, medicine and feed of the present invention.
  • the second invention is a lipid metabolism improving composition containing lactic acid bacteria belonging to Streptococcus thermophilus as a new solution for suppressing the accumulation of excess fat and obesity in a living body.
  • the present invention provides a composition for improving lipid metabolism that improves the metabolism of adipocytes, such as promoting differentiation into cells and activating brown adipocytes, and foods, pharmaceuticals, and feeds containing such compositions.
  • the second invention is a new solution for improving metabolic syndrome, a composition for improving metabolic syndrome including lactic acid bacteria belonging to Streptococcus thermophilus, and a food, a medicine for improving metabolic syndrome containing such a composition, And providing feed. Therefore, improvement of adipocyte metabolism and metabolic syndrome can be expected in a simple and safe manner by ingesting the above composition, food, medicine and feed of the second invention.
  • the present inventors have conceived that it is possible to prevent the accumulation of fat in the liver by suppressing the synthesis of fat in the liver in addition to suppressing the accumulation of fat in the adipose tissue.
  • lactic acid bacteria belonging to Streptococcus thermophilus prevent the accumulation of fat in the liver.
  • the first invention is based on the above findings.
  • the present invention relates to a lipid metabolism improving composition containing lactic acid bacteria belonging to Streptococcus thermophilus and foods, pharmaceuticals, and feeds containing the same, and Streptococcus thermophilus used in the present invention is a 16S ribosomal RNA gene sequence analysis.
  • Streptococcus thermophilus SBT1277 (FERM BP-3234), SBT1063 (NITE P-02398), SBT1021A (FERM P-10358), SBT10137 (FERM P19530, FERM P-19531) -9442), SBT0113 (FERM P-9443), SBT0144 (FERM P-16638), SBT1035 (FERM P-16945) and ATCC 19258, among which SBT1063 (NITE P-02398), SBT1277 (FERM BP- 03234) is particularly preferred.
  • Streptococcus thermophilus used in the present invention may be live cells, dead cells, cell cultures, cytoplasm or cell wall fractions obtained by treating these cells with enzymes or physical means, One or more of these can be used.
  • a composition containing lactic acid bacteria belonging to Streptococcus thermophilus which is an active ingredient of the present invention, can be obtained according to a conventional method for preparing a culture of lactic acid bacteria.
  • various media such as a milk medium or a medium containing milk components and a semi-synthetic medium not containing the milk medium can be used.
  • the culture of lactic acid bacteria can be obtained by inoculating the sterilized medium with lactic acid bacteria belonging to Streptococcus thermophilus and culturing at about 20 ° C. to 45 ° C. for 5 hours to several days.
  • the culture temperature and period may be appropriately adjusted according to the Streptococcus thermophilus strain used and the desired number of bacteria.
  • the culture containing lactic acid bacteria belonging to Streptococcus thermophilus obtained by culturing can be used as a composition containing lactic acid bacteria belonging to Streptococcus thermophilus as an active ingredient of the present invention as it is.
  • a composition obtained by subjecting the culture to a treatment such as centrifugation, membrane concentration, drying, or freeze-drying can also be used.
  • a 11.55% skim milk medium supplemented with 0.5% yeast extract (manufactured by Asahi Breweries) is sterilized at 115 ° C. for 20 minutes.
  • An example of the preparation method includes a step of inoculating Streptococcus thermophilus SBT1277 (FERM BP-03234) after cooling to room temperature, culturing at 37 ° C. for 16 hours, and freeze-drying and pulverizing the obtained culture in a mortar.
  • the intake amount of lactic acid bacteria belonging to Streptococcus thermophilus which is an active ingredient of the present invention may be 5 ⁇ 10 8 or more in the case where Streptococcus thermophilus is viable, 1 ⁇ 10 10 or more is more preferable, and 1 ⁇ 10 11 or more is most preferable.
  • Streptococcus thermophilus When Streptococcus thermophilus is dead, it may be an amount corresponding to the number of bacteria equivalent to the above live bacteria. When both live and dead bacteria are included, the total of the live and dead bacteria may be an amount corresponding to the number of bacteria equivalent to the above live bacteria.
  • the daily intake per adult may be 0.1 mg to 5000 mg, preferably 100 mg to 2500 mg, preferably 500 mg More preferably, it is 1000 mg or less.
  • composition for improving lipid metabolism containing lactic acid bacteria belonging to Streptococcus thermophilus of the present invention and the food, medicine and feed containing the composition, the expression of fatty acid synthesis related genes in the liver by ingesting the above intake , Reducing the accumulation of triglycerides and total lipids in the liver, reducing plasma triglyceride levels, and further reducing body weight.
  • Lipid abnormalities that occur when the balance of cholesterol and triglycerides (neutral fat) in the blood is lost by ingesting the above-described composition for improving lipid metabolism and foods, pharmaceuticals, and feeds containing such compositions. Prevention and improvement of this are expected.
  • diseases caused by dyslipidemia eg, insulin resistance, diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cirrhosis, liver cancer
  • arteriosclerotic diseases eg, hypertension, narrowing
  • cardiomyopathy myocardial infarction, cerebral infarction, cerebral hemorrhage, aortic aneurysm, renal infarction, obstructive arteriosclerosis are expected.
  • composition for improving lipid metabolism containing lactic acid bacteria belonging to Streptococcus thermophilus and the effect on lipid metabolism of foods, pharmaceuticals, and feeds containing such a composition according to the present invention are described in Example A in vitro or in vivo. It can be evaluated by the following test.
  • the composition containing Streptococcus thermophilus of the present invention can be blended in any food, and the amount of the composition is adjusted in consideration of the intake of the above-mentioned active ingredients. It only has to be manufactured.
  • foods include cheese, fermented milk, dairy lactic acid bacteria beverages, lactic acid bacteria beverages, butter, margarine and other dairy products, milk beverages, fruit juice beverages, soft drinks and other beverages, jelly, candy, pudding, mayonnaise and other egg processing Goods, confectionery such as butter cake, bread, and various types of powdered milk, infant foods, nutritional compositions, and the like can be exemplified.
  • composition containing Streptococcus thermophilus of the present invention can be blended in any medicine, and the amount of the composition is adjusted in consideration of the intake of the above-mentioned active ingredients. It may be manufactured by.
  • composition containing Streptococcus thermophilus of the present invention can be blended in any feed, and the blending amount of the composition is adjusted in consideration of the intake amount of the above-mentioned active ingredients. It may be manufactured by.
  • Example A Example A and Test Example A are shown below and the present invention will be described in detail, but the present invention is not limited by these.
  • Example A1 Preparation of a composition containing Streptococcus thermophilus 0.5% yeast extract (manufactured by Asahi Breweries) sterilized by Streptococcus thermophilus SBT1277 (FERM BP-03234) at 115 ° C for 20 minutes The culture was carried out at 37 ° C. for 16 hours in the added 11.55% skim milk medium for 3 or more generations and activated. This was inoculated with 3% of the same medium and cultured at 37 ° C. for 16 hours.
  • the obtained culture was freeze-dried and then pulverized in a mortar to obtain a composition containing powdered Streptococcus thermophilus.
  • the number of viable bacteria of Streptococcus thermophilus SBT1277 in the above composition was 3.6 ⁇ 10 9 cfu / g.
  • Test method 1-1 Cell Culture Method HepG2 cells, which are established hepatoma cells, were seeded in 12-well plates and cultured in 10% FBS-containing DMEM medium until confluent. After further overnight culture in FBS-free DMEM medium, skim milk medium (final concentration 5 mg / mL), or skim milk culture of lactic acid bacteria of (1) to (5) below (final concentration 5 mg / mL) are added. Then, the medium was replaced with each added FBS-free DMEM medium and cultured for 2 days.
  • strains with numbers starting with JCM can be purchased from the Microbial Materials Development Department, RIKEN BioResource Center.
  • strains with numbers beginning with ATCC can be purchased from the American Type Culture Collection, an American microorganism distribution agency.
  • ⁇ Lactic acid bacteria> (1) Lactobacillus gasseri (JCM1131) (2) Bifidobacterium longum (JCM1217) (3) Lactobacillus helveticus (JCM1120) (4) Lactobacillus delbrueckii subsp. Bulgaricus (ATCC 11842) (5) Streptococcus thermophilus (ATCC 19258)
  • SREBP1c-F TCGCGGAGCCATGGATT (SEQ ID NO: 1) SREBP1c-R; GCCAGGGAAGTCACTGTCTTG (SEQ ID NO: 2 in the sequence listing) FAS-F; GCAAATTCGACCTTTCTCAGAAC (SEQ ID NO: 3) FAS-R; GGACCCCGTGGAAATTCA (SEQ ID NO: 4) SCD1-F; TGTGGAGCCCACCCTCTTAC (SEQ ID NO: 5) SCD1-R; ACGAGCCCATTCATAGACATCA (SEQ ID NO: 6 in the sequence listing) Cyclophilin-F; GCGTCTCCTTTGAGCTGTTTG (SEQ ID NO: 7) Cyclophilin-R; ATCCTTTCTCTCCAGTGCTCAGA (SEQ ID NO: 8)
  • Test Example A2 Effect of Streptococcus thermophilus on expression of fatty acid synthesis-related genes in hepatocytes
  • Test Method As in Test Example A1, after seeding HepG2 cells in a 12-well plate and culturing, skim milk medium (final concentration 1 mg / mL), Streptococcus thermophilus ATCC 19258, or SBT1277 (FERM BP-3234), or SBT1063 (NITE P-02398) nonfat milk culture (the final concentration was 0.1, 0.5, 1 mg / mL) was replaced with FBS-free DMEM medium and cultured for 2 days. Thereafter, RNA was purified in the same manner as in Test Example A1, and the expression level of fatty acid synthesis-related genes (SREBP-1c, FAS) was quantified.
  • SREBP-1c, FAS expression level of fatty acid synthesis
  • Streptococcus thermophilus SBT1277 and SBT1063 reduced the expression of fatty acid synthesis-related genes in hepatocytes even at concentrations of 1 mg / mL or less, which is not different in Streptococcus thermophilus ATCC 19258.
  • Test Example A3 Effect of Streptococcus thermophilus on accumulation of triglyceride in hepatocytes The effect of Streptococcus thermophilus on accumulation of triglyceride in hepatocytes was examined. 1. Test Method As in Test Example A1, HepG2 cells are seeded in a 12-well plate and cultured, and then skim milk medium (final concentration 0.2 mg / mL), Streptococcus thermophilus ATCC 19258, SBT1277, or SBT1063 skim milk culture The culture medium was replaced with an FBS-free DMEM medium supplemented with a product (both at a final concentration of 0.5 mg / mL) and cultured for 2 days.
  • skim milk medium final concentration 0.2 mg / mL
  • Streptococcus thermophilus ATCC 19258, SBT1277 or SBT1063 skim milk culture
  • the culture medium was replaced with an FBS-free DMEM medium supplemented with a product (both at a final concentration
  • the cells were disrupted in extraction buffer (50 mM Tris-HCl, pH 7.5, 0.1% Triton X-100) and centrifuged, and the triglyceride concentration in the supernatant was determined as triglyceride E test Wako (manufactured by Wako Pure Chemical Industries, Ltd.). It measured using. The protein concentration was measured using a BCA protein assay (manufactured by Thermo Fisher Scientific).
  • Test Example A4 Lipid metabolism improving effect of Streptococcus thermophilus SBT1277 (FERM BP-03234) The lipid metabolic improving effect of Streptococcus thermophilus SBT1277 (FERM BP-3234) was examined using mice.
  • Test method 1-1 Breeding method After 5 weeks old male C57BL6 / JJcl mice were acclimated for 1 week, 20 mice were bred in 2 groups and kept for 8 weeks under the following conditions so that there was no difference in average body weight.
  • (1) Control group Based on the AIN76 feed a high fat diet prepared to contain 20% skim milk medium and 20% fat was fed.
  • Thermofils group instead of the skim milk medium of the control group feed, a high fat diet prepared to contain 20% of the Streptococcus thermophilus SBT1277 skim milk culture prepared in Example A1 was fed.
  • the total lipid concentration was measured by weighing the lipid weight after extraction, and the triglyceride concentration was measured using Triglyceride E-Test Wako after dissolving the extracted lipid in isopropanol. Moreover, the density
  • Test results (1) Body weight, liver weight, plasma triglyceride concentration The results are shown in Table A4. The thermophilus group had a significant weight loss compared to the control group. Plasma triglyceride levels were also significantly reduced.
  • Streptococcus thermophilus improves the metabolism and lowers the body weight by reducing the neutral fat in the blood and suppressing the accumulation of fat in the liver.
  • Example A2 Production of composition for improving lipid metabolism Centrifugation of Streptococcus thermophilus SBT1277 M17 medium (manufactured by OXOID) at 4 ° C. and 7000 rpm for 15 minutes, followed by washing with sterile water and centrifugation Repeated 3 times to obtain washed cells. The washed cells were freeze-dried to obtain cell powder. This can be used as it is as a composition for improving lipid metabolism.
  • the viable cell count of Streptococcus thermophilus SBT1277 in the above composition was 1.6 ⁇ 10 11 cfu / g.
  • Example A3 Manufacture of a drug for improving lipid metabolism 4 parts of skimmed milk powder were mixed with 1 part of the bacterial powder prepared in Example A2, and this mixed powder was tableted 1 g at a time by a conventional method, A tablet containing 200 mg of cells of Streptococcus thermophilus SBT1277 was prepared.
  • Example A4 Production of fermented milk for improving lipid metabolism 10% reduced skim milk medium was sterilized at 115 ° C for 15 minutes, then inoculated with Streptococcus thermophilus SBT1277, cultured at 37 ° C for 16 hours, and skim milk culture was prepared. Fermented milk (16% nonfat dry milk + 3% glucose) sterilized at 100 ° C. for 10 minutes was inoculated and fermented at 39 ° C. for 10 hours to obtain fermented milk for lipid metabolism improvement. The viable cell count of Streptococcus thermophilus SBT1277 in the above fermented milk was 1.8 ⁇ 10 9 cfu / g.
  • Example A5 Production of lactic acid bacteria beverage for improving lipid metabolism
  • Streptococcus thermophilus SBT1277 cultured in 10% reduced skim milk medium was sterilized at 95 ° C. for 90 minutes in 10 g of fermented mix (16% nonfat dry milk + 3% glucose) 3% Then, the mixture was cultured at 35 ° C. for 20 hours. 10 g of this culture was mixed with 40 g of isomerized sugar (BRIX 15%) to obtain a lactic acid bacteria beverage for improving lipid metabolism.
  • the number of viable bacteria of Streptococcus thermophilus SBT1277 in the above lactic acid bacteria beverage was 4 ⁇ 10 8 cfu / g.
  • Example A6 Production of composition for improving lipid metabolism After sterilization of reduced skim milk medium (13% by weight skim milk powder, 0.5% yeast extract) at 95 ° C for 30 minutes, Streptococcus thermophilus SBT1277 was inoculated. After culturing at 37 ° C. for 16 hours, the obtained culture was centrifuged at 5000 rpm for 20 minutes to obtain a culture supernatant from which the precipitate was removed. This can be used as it is as a composition for improving lipid metabolism.
  • reduced skim milk medium (13% by weight skim milk powder, 0.5% yeast extract
  • Streptococcus thermophilus SBT1277 was inoculated. After culturing at 37 ° C. for 16 hours, the obtained culture was centrifuged at 5000 rpm for 20 minutes to obtain a culture supernatant from which the precipitate was removed. This can be used as it is as a composition for improving lipid metabolism.
  • Example A7 Production of health food for improving lipid metabolism 50 g of the culture powder of Streptococcus thermophilus SBT1277 obtained in Example A1, 40 g of an equal mixture of vitamin C and citric acid, 100 g of granulated sugar, corn starch and lactose 60 g of an equal amount of the mixture was added and mixed. The mixture was packed in a stick-shaped bag to obtain a health food for improving lipid metabolism.
  • Example A8 Manufacture of feed for improving lipid metabolism Soybean meal 12 kg, skim milk powder 14 kg, soybean oil 4 kg, corn oil 2 kg, palm oil 23.2 kg, corn starch 14 kg, wheat flour 9 kg, bran 2 kg, vitamin mixture 5 kg, cellulose 2 8 kg and 2 kg of the mineral mixture were sterilized at 120 ° C. for 4 minutes, and 10 kg of the culture powder of Streptococcus thermophilus SBT1277 obtained in Example A1 was blended to produce a feed for improving lipid metabolism.
  • Example A9 Production of cheese for improving lipid metabolism
  • the raw material milk was sterilized by heating (75 ° C, 15 seconds), cooled to 30 ° C, and 0.01% calcium chloride was added. Furthermore, 0.7% of commercially available lactic acid bacteria starter (LD starter, Christian Hansen) and 1% of Streptococcus thermophilus SBT1277 culture were added, and 0.003% of rennet was further added to coagulate the milk.
  • the curd thus obtained was cut and stirred until the pH was 6.2 to 6.1, and the whey was discharged to obtain curd grains. Then, the curd grains were packed, pressed, further salted, and aged at 10 ° C.
  • the present inventors improve metabolism in adipocytes, promote differentiation from white adipose precursor cells to brown adipocytes, or activate brown adipocytes to enhance energy consumption by heat production.
  • the idea was to suppress the accumulation of excess fat and obesity in the living body, and to prevent or improve metabolic syndrome and the like.
  • lactic acid bacteria belonging to Streptococcus thermophilus promote differentiation of white adipose precursor cells to brown adipocytes or activate brown adipocytes.
  • the second invention is based on the above findings.
  • the present invention relates to a composition for improving lipid metabolism that promotes differentiation of white adipose precursor cells containing lactic acid bacteria belonging to Streptococcus thermophilus into brown adipocytes, a composition for activating brown adipocytes, and a composition for improving metabolic syndrome metabolism. And foods, medicines and feeds containing them.
  • Streptococcus thermophilus used in the present invention any lactic acid bacteria classified into Streptococcus thermophilus species by a general classification method such as 16S ribosomal RNA gene sequence analysis can be used.
  • Streptococcus thermophilus SBT1277 (FERM BP-3234), SBT1063 (NITE P-02398), SBT1021A (FERM P-10358), SBT10137 (FERM P19530, FERM P-19531) ⁇ 9442), SBT0113 (FERM P-9443), SBT0144 (FERM P-16638), SBT1035 (FERM P-16945), and ATCC 19258, among which SBT1277 (FERM BP-3234) is particularly preferable.
  • Strains having numbers starting with FERM or NITE in parentheses can be obtained from the depository organizations described later, and ATCC 19258 can be purchased from the American Type Culture Collection, an American microorganism distribution organization.
  • Streptococcus thermophilus used in the present invention may be live cells, dead cells, cell cultures, cytoplasm or cell wall fractions obtained by treating these cells with enzymes or physical means, One or more of these can be used.
  • a composition containing lactic acid bacteria belonging to Streptococcus thermophilus which is an active ingredient of the present invention, can be obtained according to a conventional method for preparing a culture of lactic acid bacteria.
  • various media such as a milk medium or a medium containing milk components and a semi-synthetic medium not containing the milk medium can be used.
  • the culture of lactic acid bacteria can be obtained by inoculating the sterilized medium with lactic acid bacteria belonging to Streptococcus thermophilus and culturing at about 20 ° C. to 45 ° C. for 5 hours to several days.
  • the culture temperature and period may be appropriately adjusted according to the Streptococcus thermophilus strain used and the desired number of bacteria.
  • the culture containing lactic acid bacteria belonging to Streptococcus thermophilus obtained by culturing can be used as a composition containing lactic acid bacteria belonging to Streptococcus thermophilus as an active ingredient of the present invention as it is.
  • a composition obtained by subjecting the culture to a treatment such as centrifugation, membrane concentration, drying, or freeze-drying can also be used.
  • a 11.55% skim milk medium supplemented with 0.5% yeast extract (manufactured by Asahi Breweries) is sterilized at 115 ° C. for 20 minutes.
  • the preparation method include a step of inoculating Streptococcus thermophilus after cooling to room temperature, culturing at 37 ° C. for 16 hours, freeze-drying the obtained culture, and grinding in a mortar.
  • the intake amount of lactic acid bacteria belonging to Streptococcus thermophilus which is an active ingredient of the present invention may be 5 ⁇ 10 8 or more in the case where Streptococcus thermophilus is viable, 1 ⁇ 10 10 or more is more preferable, and 1 ⁇ 10 11 or more is most preferable.
  • Streptococcus thermophilus When Streptococcus thermophilus is dead, it may be an amount corresponding to the number of bacteria equivalent to the above live bacteria. When both live and dead bacteria are included, the total of the live and dead bacteria may be an amount corresponding to the number of bacteria equivalent to the above live bacteria.
  • the daily intake per adult may be 0.1 mg to 5000 mg, preferably 100 mg to 2500 mg, preferably 500 mg More preferably, it is 1000 mg or less.
  • composition containing lactic acid bacteria belonging to the Streptococcus thermophilus of the present invention, and the food, medicine and feed containing such a composition differentiate white fat precursor cells into brown fat cells when ingested at the above intake. Brown fat cells are activated, and subcutaneous fat and visceral fat are reduced and body weight is reduced. Furthermore, the composition containing the lactic acid bacteria belonging to Streptococcus thermophilus of the present invention as an active ingredient, and the food, medicine, and feed containing the composition are expressed in the amount of fatty acid synthesis-related gene by ingesting at the above intake.
  • diseases caused by dyslipidemia eg, insulin resistance, diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cirrhosis, liver cancer
  • arteriosclerotic diseases eg, angina pectoris
  • myocardial infarction, cerebral infarction, cerebral hemorrhage, aortic aneurysm, renal infarction, obstructive arteriosclerosis e.g., diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cirrhosis, liver cancer
  • arteriosclerotic diseases eg, angina pectoris
  • composition of the present invention comprising a lactic acid bacterium belonging to Streptococcus thermophilus as an active ingredient, and the effect of improving the metabolism of adipocytes in foods, pharmaceuticals, and feeds containing the composition are the in vivo described in Example B. It can be evaluated by testing.
  • the composition containing Streptococcus thermophilus of the present invention can be blended in any food, and the blending amount of the composition is adjusted in consideration of the intake amount of the above active ingredients. It only has to be manufactured.
  • foods include dairy products such as cheese, fermented milk, dairy lactic acid bacteria beverages, lactic acid bacteria beverages, butter and margarine, beverages such as dairy beverages, fruit juice beverages and soft drinks, and egg processed products such as jelly, candy, pudding and mayonnaise
  • confectionery and breads such as butter cake, and various types of powdered milk, infant foods, nutritional compositions and the like can be exemplified.
  • composition containing Streptococcus thermophilus of the present invention can be blended in any pharmaceutical, and the blending amount of the composition is adjusted in consideration of the intake amount of the above-mentioned active ingredients, otherwise the standard method of the desired pharmaceutical It may be manufactured according to
  • composition containing Streptococcus thermophilus of the present invention can be blended in any feed, and the blending amount of the composition is adjusted in consideration of the intake amount of the above-mentioned active ingredients. It may be manufactured according to
  • Example B Example B and Test Example B are shown below, and the present invention will be described in detail, but the present invention is not limited thereto.
  • Example B1 Preparation of a composition containing Streptococcus thermophilus Streptococcus thermophilus SBT1277 (FERM BP-03234) was sterilized at 115 ° C. for 20 minutes and added with 0.5% yeast extract (Asahi Breweries) at 11.55% skim milk medium at 37 ° C., 16 It was activated by culturing for 3 or more times. This was inoculated with 3% of the same medium and cultured at 37 ° C. for 16 hours. The obtained culture was freeze-dried and then pulverized in a mortar to obtain a composition containing powdered Streptococcus thermophilus. The number of viable bacteria of Streptococcus thermophilus SBT1277 in the above composition was 3.6 ⁇ 10 9 cfu / g.
  • Test Example B1 Using mice, the metabolic improvement effect of Streptococcus thermophilus was examined.
  • Test method 1-1 Breeding method After 5 weeks old male C57BL6 / JJcl mice were acclimated for 1 week, 20 mice were bred in 2 groups and kept for 8 weeks under the following conditions so that there was no difference in average body weight.
  • Control group AIN76 feed was fed with a high fat diet prepared to contain 20% skim milk medium and 20% fat.
  • Thermofils group Instead of the skim milk medium of the control group feed, a high fat diet prepared to contain 20% of a composition (fat milk culture) containing Streptococcus thermophilus SBT1277 prepared in Example B1 Ingested
  • Measurement method (1) Body weight, weight of each tissue, plasma parameter After measuring body weight, blood, liver, groin adipose tissue, peritesticular adipose tissue, mesenteric adipose tissue, interscapular brown adipose tissue were collected. Triglyceride and insulin concentrations were measured using plasma prepared from blood. Triglyceride E-Test Wako was used for measurement of triglyceride concentration, and an ultrasensitive mouse insulin measurement kit (manufactured by Morinaga Bioscience Laboratories) was used for insulin measurement.
  • ReverseTra Ace qPCR RT Master Mix manufactured by Toyobo Co., Ltd.
  • real-time PCR was performed with THUNDERBIRD qPCR Mix (manufactured by Toyobo Co., Ltd.), and the expression level of the gene was analyzed.
  • fatty acid synthesis-related genes SREBP-1c, FAS, SCD1
  • cholesterol synthesis-related gene SREBP-2
  • gluconeogenesis-related gene G6Pase
  • UCP1 gene which is a marker of brown adipocyte activation
  • MCP1 gene which is an inflammation marker
  • Test results (1) Body weight, weight of each tissue, plasma parameters The results are shown in Table B1. In the Thermophilus group, body weight was significantly reduced compared to the control group. In addition, the weight of the brown adipose tissue between the liver and the scapula is also significantly decreased, and the weight of the inguinal adipose tissue corresponding to subcutaneous fat and the weight of peritesticular adipose tissue and mesenteric adipose tissue corresponding to visceral fat are decreasing Indicated. In addition, plasma triglyceride levels were significantly reduced.
  • Streptococcus thermophilus prevents the obesity by suppressing the accumulation of subcutaneous fat and visceral fat, reduces the neutral fat in the blood, and suppresses the accumulation of fat in the liver. Was found to improve.
  • Streptococcus thermophilus promotes the differentiation of white adipose precursor cells into brown adipocytes and also promotes activation of brown adipose tissue. It was also found that metabolic syndrome was improved by suppressing the expression of fatty acid synthesis-related genes, cholesterol synthesis-related genes, and gluconeogenesis-related genes in the liver, and further by suppressing inflammation of adipose tissue.
  • Example B2 Production of composition for improving metabolism of adipocytes Centrifugation of Streptococcus thermophilus SBT1277 M17 medium (manufactured by OXOID) at 4 ° C. and 7000 rpm for 15 minutes, followed by washing with sterile water and centrifugation Separation was repeated 3 times to obtain washed cells. The washed cells were freeze-dried to obtain cell powder. This can be used as it is as a composition for improving metabolism of fat cells.
  • the viable cell count of Streptococcus thermophilus SBT1277 in the above composition was 1.6 ⁇ 10 11 cfu / g.
  • Example B3 Manufacture of a drug for improving metabolism of fat cells 4 parts of skimmed milk powder was mixed with 1 part of the bacterial cell powder prepared in Example B2, and this mixed powder was tableted 1 g at a time by a conventional method. Thus, a tablet containing 200 mg of cells of Streptococcus thermophilus SBT1277 was prepared.
  • Example B4 Production of fermented milk for improving adipocyte metabolism 10% reduced skim milk medium was sterilized at 115 ° C for 15 minutes, then inoculated with Streptococcus thermophilus SBT1277, cultured at 37 ° C for 16 hours, and skim milk Cultures were prepared. The skim milk culture was inoculated into a fermented mix (16% skim milk powder + 3% glucose) sterilized at 100 ° C. for 10 minutes and fermented at 39 ° C. for 10 hours to obtain fermented milk for improving fat cell metabolism. The viable cell count of Streptococcus thermophilus SBT1277 in the fermented milk was 1.8 ⁇ 10 9 cfu / g.
  • Example B5 Production of lactic acid bacteria beverage for improving fat cell metabolism 10 g of fermented mix (16% nonfat dry milk + 3% glucose) obtained by sterilizing Streptococcus thermophilus SBT1277 cultured in 10% reduced nonfat milk medium at 95 ° C for 90 minutes It added so that it might become 3%, and it culture
  • Example B6 Production of a composition for improving metabolism of fat cells A reduced skim milk medium (13% by weight skim milk powder, 0.5% yeast extract) was sterilized at 95 ° C for 30 minutes and then inoculated with Streptococcus thermophilus SBT1277. The resulting culture was centrifuged at 5000 rpm for 20 minutes to obtain a culture supernatant from which the precipitate was removed. This can be used as it is as a composition for improving metabolism of fat cells.
  • Example B7 Production of health food for improving metabolism of adipocytes 50 g of the culture powder of Streptococcus thermophilus SBT1277 obtained in Example B1, 40 g of an equal mixture of vitamin C and citric acid, 100 g of granulated sugar, corn starch 60 g of an equal amount mixture of lactose and lactose was added and mixed. The mixture was packed in a stick-shaped bag to obtain a health food for improving fat cell metabolism.
  • Example B8 Production of feed for improving metabolism of fat cells Soybean meal 12 kg, skim milk powder 14 kg, soybean oil 4 kg, corn oil 2 kg, palm oil 23.2 kg, corn starch 14 kg, wheat flour 9 kg, bran 2 kg, vitamin mixture 5 kg, Blended with 2.8 kg of cellulose and 2 kg of mineral mixture, sterilized at 120 ° C. for 4 minutes, blended with 10 kg of the culture powder of Streptococcus thermophilus SBT1277 obtained in Example B1, and feed for improving metabolism of fat cells Manufactured.
  • Example B9 Production of hard natural cheese for improving metabolism of fat cells
  • the raw milk was sterilized by heating (75 ° C, 15 seconds), cooled to 30 ° C, and 0.01% calcium chloride was added.
  • 0.7% of commercially available lactic acid bacteria starter (LD starter, Christian Hansen) and 1% of Streptococcus thermophilus SBT1277 were added, and 0.003% of rennet was further added to coagulate the milk.
  • the curd thus obtained was cut and stirred until the pH was 6.2 to 6.1, and the whey was discharged to obtain curd grains. Then, the curd grains were molded, pressed, further salted and aged at 10 ° C. to produce Gouda cheese type hard natural cheese for improving fat cell metabolism containing Streptococcus thermophilus SBT1277.
  • the first invention is a composition for improving lipid metabolism comprising a lactic acid bacterium belonging to Streptococcus thermophilus as an active ingredient, a food for improving lipid metabolism, a pharmaceutical comprising the composition, And providing feed. Therefore, improvement of lipid metabolism can be expected in a simple and safe manner by ingesting the above composition, food, medicine and feed of the present invention.
  • the second invention comprises a composition for improving metabolism of adipocytes, such as promotion of differentiation from white adipose precursor cells to brown adipocytes, activation of brown adipocytes, comprising lactic acid bacteria belonging to Streptococcus thermophilus as an active ingredient, and Food for improving metabolism of adipocytes, pharmaceutical and feed containing the composition, composition for improving metabolic syndrome containing lactic acid bacteria belonging to Streptococcus thermophilus as an active ingredient, and food for improving metabolic syndrome and pharmaceutical containing the composition And providing feed.
  • improvement of adipocyte metabolism and metabolic syndrome can be expected in an easy and safe manner by ingesting the above composition, food, medicine and feed.
  • SBT1277 Name and address of the depositary institution that deposited the biological material Patent Evaluation Microorganisms Depositary Center, Patent Evaluation Microorganisms Center 2-5-2, Kazusa Kamashi, Kisarazu City, Chiba Prefecture, Japan (zip code 292-0818) Date of deposit of biological materials at Loi depository December 11, 2001 (original deposit date) January 22, 1991 (Date of transfer to deposit under the Budapest Treaty by original deposit) Deposit number FERM BP-3234 assigned by the depository in Thailand for deposit (2) SBT0104 (I) Name and address of the depositary institution that deposited the biological material Patent Evaluation Microorganisms Depositary Center, Patent Evaluation Microorganisms Center 2-5-2, Kazusa Kamashi, Kisarazu City, Chiba Prefecture, Japan (zip code 292-0818) Date of deposit of biological materials at Loi depository organization June 30, 1987 (original deposit date) Deposit number FERM P-9442 attached to the depository by the depository in Hai (3) SBT0113 (I) Name and address of the depositary institution that deposited

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fodder In General (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une composition destinée à l'amélioration du métabolisme des lipides, ladite composition comprenant une culture et/ou des cellules d'une bactérie d'acide lactique appartenant à Streptococcus thermophilus. En consommant la composition destinée à l'amélioration du métabolisme des lipides ou un aliment, un médicament ou un aliment pour animaux pour améliorer le métabolisme des lipides, comprenant chacun la composition susmentionnée, il est possible d'améliorer le métabolisme des lipides, et par conséquent de réduire le poids corporel.
PCT/JP2018/011280 2017-03-22 2018-03-22 Composition pour améliorer le métabolisme des lipides Ceased WO2018174125A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019506952A JP7606276B2 (ja) 2017-03-22 2018-03-22 脂質代謝改善用組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017056311 2017-03-22
JP2017-056312 2017-03-22
JP2017056312 2017-03-22
JP2017-056311 2017-03-22

Publications (1)

Publication Number Publication Date
WO2018174125A1 true WO2018174125A1 (fr) 2018-09-27

Family

ID=63585482

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/011280 Ceased WO2018174125A1 (fr) 2017-03-22 2018-03-22 Composition pour améliorer le métabolisme des lipides

Country Status (2)

Country Link
JP (1) JP7606276B2 (fr)
WO (1) WO2018174125A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113208114A (zh) * 2020-07-14 2021-08-06 内蒙古蒙牛乳业（集团）股份有限公司 嗜热链球菌mn002在脂代谢调节中的用途及膳食补充剂
WO2022065330A1 (fr) * 2020-09-23 2022-03-31 雪印メグミルク株式会社 Agent de prévention de l'atrophie musculaire

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10229841A (ja) * 1997-02-21 1998-09-02 Yakult Honsha Co Ltd 脂質代謝改善剤およびそれを含有する食品
JP2001302523A (ja) * 2000-04-27 2001-10-31 Meiji Milk Prod Co Ltd Ｌｄｌ酸化抑制飲食品及び医薬品
US20040120936A1 (en) * 2000-07-31 2004-06-24 Bojrab Gregory G. Enhanced composition for treatment of obesity
JP2005512590A (ja) * 2001-12-21 2005-05-12 アクティアル・ファルマセウティカ・ソシエダデ・ポル・クオタス・デ・レスポンサビリダデ・リミターダ 乳酸菌の新規株およびそれを含む食用組成物、薬剤および獣医製品
JP2010057465A (ja) * 2008-08-04 2010-03-18 Takanashi Milk Products Co Ltd 機能性飲食品
JP2011516402A (ja) * 2008-03-07 2011-05-26 雪印乳業株式会社 アディポネクチン分泌促進及び／又は減少抑制剤
WO2015172191A1 (fr) * 2014-05-12 2015-11-19 Medlab Ip Pty Ltd Compositions probiotiques et leurs utilisations pour le traitement de troubles liés à l'obésité

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0732702B2 (ja) * 1990-02-23 1995-04-12 雪印乳業株式会社 新規乳酸菌、その産生する抗菌物質、この乳酸菌を含有する発酵乳用スターター及びそれを用いた発酵乳の製造方法
JP2673333B2 (ja) * 1993-09-30 1997-11-05 雪印乳業株式会社 乳酸菌生育促進剤

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10229841A (ja) * 1997-02-21 1998-09-02 Yakult Honsha Co Ltd 脂質代謝改善剤およびそれを含有する食品
JP2001302523A (ja) * 2000-04-27 2001-10-31 Meiji Milk Prod Co Ltd Ｌｄｌ酸化抑制飲食品及び医薬品
US20040120936A1 (en) * 2000-07-31 2004-06-24 Bojrab Gregory G. Enhanced composition for treatment of obesity
JP2005512590A (ja) * 2001-12-21 2005-05-12 アクティアル・ファルマセウティカ・ソシエダデ・ポル・クオタス・デ・レスポンサビリダデ・リミターダ 乳酸菌の新規株およびそれを含む食用組成物、薬剤および獣医製品
JP2011516402A (ja) * 2008-03-07 2011-05-26 雪印乳業株式会社 アディポネクチン分泌促進及び／又は減少抑制剤
JP2010057465A (ja) * 2008-08-04 2010-03-18 Takanashi Milk Products Co Ltd 機能性飲食品
WO2015172191A1 (fr) * 2014-05-12 2015-11-19 Medlab Ip Pty Ltd Compositions probiotiques et leurs utilisations pour le traitement de troubles liés à l'obésité

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KABUKI, T. ET AL.: "Gene cluster for biosynthesis of thermophilin 1277 - a lantibiotic produced by Streptococcus thermophilus SBT1277, and heterologous expression of Tepl, a novel immunity peptide", JOURNAL OF APPLIED MICROBIOLOGY, vol. 110, 2010, pages 641 - 649, XP055558640 *
KAWASE MANABU ET AL.: "Serum Cholesterol-lowering Effect of Fermented Milk with Streptococcus thermophilus TMC1543", ANIMAL SCIENCE JOURNAL, vol. 72, no. 1, 2001, pages 54 - 62, XP055558633 *
PULUSANI, S. R. ET AL.: "Whole Body, Liver and Plasma Cholesterol Levels in Rats Fed Thermophilus, Bulgaricus and Acidophilus Milks", JOURNAL OF FOOD SCIENCE, vol. 48, 1983, pages 280 - 281, XP055558649 *
TAKANASHI, NAOYA ET AL.: "Effects of improving liver metabolism by skim milk culture of Streptococcus thermophilus strain SBT1277", LECTURE ABSTRACT IN MEETING OF JAPAN SOCIETY OF NUTRITION AND FOOD SCIENCE, vol. 71, pages 211 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113208114A (zh) * 2020-07-14 2021-08-06 内蒙古蒙牛乳业（集团）股份有限公司 嗜热链球菌mn002在脂代谢调节中的用途及膳食补充剂
WO2022065330A1 (fr) * 2020-09-23 2022-03-31 雪印メグミルク株式会社 Agent de prévention de l'atrophie musculaire

Also Published As

Publication number Publication date
JPWO2018174125A1 (ja) 2020-01-23
JP7606276B2 (ja) 2024-12-25

Similar Documents

Publication Publication Date Title
AU2008222007B2 (en) Agent for reducing visceral fat
TWI572354B (zh) 抑制發炎之組成物
JP4834798B2 (ja) 新規ビフィズス菌、耐糖能改善剤、および抗肥満剤
JP5569710B2 (ja) 肥満予防又は改善剤
JP6339526B2 (ja) 筋肉の分解抑制剤
JP5804542B2 (ja) 脂肪肝予防及び／又は抑制剤
KR20220168575A (ko) 대사성 질환의 예방 및 치료를 위한 락토바실러스 퍼멘텀 균주 및 조절 t 세포의 병용 투여 용도
TW201705969A (zh) 新穎馬利乳酸桿菌ａｐｓ１及其用途
WO2020091179A9 (fr) Composition de prévention ou de traitement de l'ostéoporose secondaire comprenant un probiotique en tant que principe actif
US11484557B2 (en) Human-derived Lactobacillus fermentum MG4231 or Lactobacillus fermentum MG4244 strain having anti-obesity activity, and composition comprising same
WO2005092122A1 (fr) Composition comprenant un extrait de yucca, un extrait de quillaia et une bacterie d'acide lactique et aliment et boisson contenant la composition
JP7606276B2 (ja) 脂質代謝改善用組成物
JP5229977B2 (ja) 血中アディポネクチン濃度増加促進及び／又は減少抑制剤
JP6894242B2 (ja) 非アルコール性肝障害抑制剤
JP6761268B2 (ja) Ｍｋｐ−１誘導剤
JP7627369B2 (ja) 糖吸収促進用組成物
JP2012012321A (ja) 血中可溶性細胞間接着因子濃度上昇抑制剤
JP5873904B1 (ja) レストレスレッグス症候群改善用組成物
WO2025206186A1 (fr) Composition pour soulager le stress, aliment humain et boisson, médicament et aliment animal
JP2025102646A (ja) 肝障害抑制用組成物
JP5851242B2 (ja) チオレドキシン誘導活性を有する乳酸菌ならびにチオレドキシンを介する生体傷害の予防および／または改善用の飲食品および医薬品
JP2007091704A (ja) ＩｇＥ産生抑制剤、ＩｇＥ産生抑制用飲食品、抗アレルギー剤および抗アレルギー用飲食品
JP2017066086A (ja) デオキシコール酸低減剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18770700

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2019506952

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18770700

Country of ref document: EP

Kind code of ref document: A1